SIM2 Peptide Inhibits Cancer Lipogenesis via DAXX Competition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those targeting de novo lipogenesis, face challenges in understanding the mechanisms controlling SREBP-mediated transcription and identifying effective biomarkers and therapeutic agents, as existing drugs like statins show mixed results in clinical studies.
Innovation Solution
The use of a polypeptide derived from the C-terminal SUMO-interacting motif of the DAXX protein, specifically the SIM2 peptide, which competes with endogenous DAXX for SUMO binding, is proposed to inhibit de novo lipogenesis and tumor growth by disrupting the DAXX-SREBP interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statins are used to inhibit HMG-CoA reductase and lower blood cholesterol levels, then lipid synthesis is reduced, but the anticancer effect remains controversial and unclear in clinical studies
Solution Approach 1:
The patent segments the lipogenesis pathway into specific targetable components by identifying DAXX as a distinct regulatory protein that controls SREBP-mediated transcription. Instead of using broad inhibitors like statins, the invention targets the specific DAXX-SREBP interaction, thereby segmenting the therapeutic approach to achieve more reliable and mechanism-specific anticancer effects while maintaining lipid synthesis control.
Solution Approach 2:
The patent introduces DAXX as an intermediary molecule that mediates between upstream signaling pathways and the SREBP transcription factors. By targeting DAXX as this intermediary, the invention creates a more precise control point in the lipogenesis pathway, allowing for reliable inhibition of cancer cell lipid synthesis without the controversial effects observed with statins.
2Quantity of substance
If de novo lipogenesis is inhibited in cancer cells, then lipid synthesis for membrane and signaling molecules is reduced, but understanding the controlling mechanisms and identifying biomarkers remains challenging
Solution Approach 1:
The patent extracts DAXX as a discrete, measurable biomarker from the complex SREBP-mediated transcription pathway. By identifying DAXX as a specific protein that can be detected and measured, the invention simplifies the monitoring of lipogenesis inhibition efficacy and provides a clear biomarker for treatment response assessment, thereby reducing the difficulty of detecting and measuring mechanism control.
Solution Approach 2:
The patent replaces the complex mechanical system of SREBP-mediated transcriptional regulation with a more straightforward protein-protein interaction target (DAXX-SREBP binding). This substitution simplifies the mechanistic understanding and allows for easier detection and measurement through protein level assessments, making biomarker identification more feasible.
3Quantity of substance
If DAXX is targeted to disrupt the DAXX-SREBP interaction, then de novo lipogenesis is inhibited, but the complexity of identifying effective therapeutic agents increases
Solution Approach 1:
The patent extracts the SIM2 peptide sequence from the full-length DAXX protein to create a simplified therapeutic agent. This extracted peptide specifically targets the DAXX-SREBP interaction interface, thereby reducing the complexity of drug development compared to using full-length proteins or small molecule inhibitors, while maintaining the ability to inhibit de novo lipogenesis effectively.
Solution Approach 2:
The patent creates a simplified copy (SIM2 peptide) that replicates the critical functional domain of DAXX responsible for SREBP binding. This peptide copy is easier to produce, administer, and study than full-length DAXX or complex small molecules, thereby reducing therapeutic agent development complexity while preserving the inhibitory function against de novo lipogenesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SIM2 peptide effectively downregulates lipogenic pathways, reducing lipid synthesis and tumor growth, establishing DAXX as a key regulator of cancer lipogenesis and offering a novel therapeutic target for cancer therapy.
Implementation Method 1
a polypeptide derived from the C-terminal SUMO-interacting motif of the DAXX protein, specifically the SIM2 peptide, which competes with endogenous DAXX for SUMO binding
Data Source
AI summary
Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.